Health
New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2 – News-Medical.Net
In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-C…
In a groundbreaking bioRxiv* study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.
In response to the ongoing health crisis brought by th…
-
General21 hours agoFederal government funding extends cohealth GP services until July 2026
-
Business23 hours agoWhat I’d buy if I had to invest $20,000 in ASX 200 shares before the weekend
-
General5 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
Noosa News23 hours agoAlleged violence within the CFMEU a ‘cancer’, administrator tells Queensland inquiry